ORNBV.HE
Strong BuyPremium GrowerOrion Oyj · Healthcare · Finland · $13.1B · Avg Vol: $14M/d
Premium Grower: Strong business with the market behind it, but you are paying up for it.
ABOUT ORION OYJ
Read
Orion Oyj (Class B) is a leading Finnish pharmaceutical developer and manufacturer specializing in proprietary treatments for neurological and oncological conditions, alongside generic medicines. The company maintains a dominant market share in Finland and leverages global licensing agreements to commercialize its proprietary drug discoveries. Class B shares carry lower voting rights but offer high liquidity for institutional investors seeking exposure to Orion's stable cash flows and R&D pipeline.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.3B | 1.2B | 1.5B | 1.9B | 12.1% | 2.1B | 2.1B | 2.4B | 12.1% |
| EPS (EUR) | 2.49 | 1.54 | 2.35 | 3.56 | 12.7% | 4.21 | 4.02 | 4.75 | 15.5% |
| Shares | 140.2M | 140.4M | 140.5M | 140.7M | +0.4% | 109.1M | — | — | — |
| Debt | 214.0M | 200.1M | 327.3M | 305.3M | 12.6% | 133.6M | — | — | — |
| Equity | 908.1M | 890.1M | 1.0B | 1.3B | 12.3% | — | — | — | — |
| Op CF | 434.4M | 119.0M | 293.4M | 316.8M | -10.0% | 474.9M | — | — | — |
| Inv CF | -154.3M | -108.4M | -85.2M | -98.6M | — | — | — | — | — |
| Fin CF | -159.8M | -243.2M | -108.8M | -263.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ORNBV.HE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ORNBV.HE | Orion Oyj(you) | $13.1B | 95 | Strong Buy |
| TTALO.HE | Terveystalo Oyj | $1.1B | 88 | Strong Buy |
| PIHLIS.HE | Pihlajalinna Oyj | $278M | 83 | Strong Buy |
| ORIOLA.HE | Oriola Oyj | $191M | 67 | Buy |
| REG1V.HE | Revenio Group Oyj | $435M | 44 | Hold |
| NANOFS.ST | Nanoform Finland Oyj | $77M | 37 | Hold |
| NXTMH.HE | Nexstim Plc | $79M | 27 | Sell |
| MODU.HE | Modulight Oyj | $51M | 32 | Sell |
| FARN.L | Faron Pharmaceuticals Oy | $95M | 7 | Strong Sell |
| OPTOMED.HE | Optomed Oyj | $59M | 16 | Strong Sell |
Peer medians: ROE -22.3% · P/E 14.5x · Gross margin 67.8%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.